Ozempic could be the next target of Medicare drug price negotiations – here’s why
Wall Street analysts expect Ozempic to be selected for price negotiations in 2025 due to the amount of money Medicare Part D already spends on the drug.
Qualcomm banks on AI to get a bigger share of the automotive chip market
Qualcomm is hoping to capitalize on the hype around generative AI to convince automakers to buy more of its chips.
61% of Americans are living paycheck to paycheck — inflation is still squeezing budgets
More than half of all U.S. adults currently live paycheck to paycheck, according to a new report.
Investors are getting bearish on China — but see other upside opportunities in Asia
Although China’s slowing economy is reducing confidence in global growth, some investors see other promising investment opportunities elsewhere in Asia.
Salesforce shares pop on earnings beat and optimistic forecast
Salesforce saw gains in all five product categories, and CEO Marc Benioff sees more growth from artificial intelligence capabilities
Google now tells you the cheapest dates to book a flight: Here’s how
Google recently updated Google Flights with more information that can help you save money by booking a trip during a certain time.
HHS calls for easing restrictions on marijuana, sending cannabis stocks higher
That move could potentially expand the market for cannabis, sending shares of Canopy Growth, Tilray Brands and Cronos Group higher.
How to stop Meta from using some of your personal data to train generative AI models
Facebook users can now delete their personal information found in the third-party sources that Meta uses to train generative artificial intelligence models.
Food insecurity from Russia’s war in Ukraine has triggered instability in vulnerable countries, spy agency says
The unclassified 8-page report was mandated by Congress.
Medicare drug price negotiations may have a muted impact on drugmakers in the near term
Many of the drugs are already facing strong competition from other branded medications or patent expirations that will open the market to generic alternatives.
